丰原药业(000153) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was ¥863,882,165.30, representing a 17.48% increase compared to ¥735,342,498.17 in the same period last year[9] - Net profit attributable to shareholders was ¥27,285,357.83, up 27.56% from ¥21,389,763.31 year-over-year[9] - The net profit after deducting non-recurring gains and losses was ¥23,567,920.84, a significant increase of 79.86% compared to ¥13,103,247.63 in the previous year[9] - Basic earnings per share rose to ¥0.0874, reflecting a 27.59% increase from ¥0.0685 in the previous year[9] - Total operating revenue for Q1 2021 was CNY 863,882,165.30, an increase of 17.5% compared to CNY 735,342,498.17 in the same period last year[35] - Net profit for Q1 2021 reached CNY 26,599,550.42, representing a 24.5% increase from CNY 21,339,192.03 in Q1 2020[36] - The company reported a total comprehensive income of CNY 27,488,070.73, up from CNY 20,276,139.47, representing a growth of 35.5%[36] Cash Flow - The net cash flow from operating activities reached ¥36,640,215.97, marking a substantial increase of 258.50% from ¥10,220,384.88 in the same quarter last year[9] - Net cash flow from operating activities increased by 258.50% to ¥36,640,215.97, driven by higher cash receipts from sales and services[15] - Cash flow from operating activities generated a net cash inflow of ¥36,640,215.97, a significant increase from ¥10,220,384.88 in Q1 2020[43] - The cash inflow from financing activities in Q1 2021 was 189,301,944.44 CNY, up from 151,624,682.53 CNY in Q1 2020, representing an increase of about 24.8%[47] - The net cash flow from financing activities was -8,999,501.45 CNY in Q1 2021, significantly improved from -66,304,454.40 CNY in Q1 2020[47] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,784,011,803.95, a 4.06% increase from ¥3,636,207,572.40 at the end of the previous year[9] - Total current assets increased to CNY 1,780,002,382.97 as of March 31, 2021, up from CNY 1,738,288,251.02 on December 31, 2020, representing a growth of approximately 2.5%[27] - Total liabilities amounted to CNY 2,309,040,309.63, up from CNY 2,188,230,845.23, indicating a rise of about 5.5%[29] - The total assets as of January 1, 2021, were 3,703,649,907.21 CNY, an increase of 67,442,334.81 CNY compared to the previous year[50] - The total liabilities increased to 2,255,673,180.04 CNY as of January 1, 2021, reflecting an increase of 67,442,334.81 CNY from the previous year[50] Research and Development - R&D expenses surged by 302.68% to ¥24,684,328.32, indicating a significant increase in investment in research and development[15] - Research and development expenses increased significantly to CNY 24,684,328.32, compared to CNY 6,130,083.03 in the previous year, marking a rise of 303.5%[35] - The company is investing 5 million in R&D for new drug development[55] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 42,662[12] - The top shareholder, Anhui Wuwei Pharmaceutical Factory, holds 11.48% of the shares, totaling 35,842,137 shares[12] - Net assets attributable to shareholders increased to ¥1,441,663,354.54, up 1.99% from ¥1,413,489,476.40 at the end of the last year[9] - The equity attributable to shareholders rose to CNY 1,441,663,354.54, up from CNY 1,413,489,476.40, representing an increase of approximately 2%[29] Government and Regulatory Compliance - The company received government subsidies amounting to ¥4,849,180.58 during the reporting period[10] - There were no violations regarding external guarantees during the reporting period, reflecting sound financial governance[22] - The company did not engage in any entrusted financial management during the reporting period, maintaining a straightforward financial approach[21] - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period, ensuring financial integrity[23] Future Outlook - Future outlook includes a projected revenue growth of 10% for the next quarter[55] - The company aims to increase its market share by 5% through strategic partnerships[55] - New product launches are expected to contribute an additional 3% to overall revenue in the next fiscal year[55] - Market expansion plans include entering two new provinces by the end of 2021[55] - The company is exploring potential acquisitions to enhance its product portfolio[55] Miscellaneous - The company has no derivative investments during the reporting period, indicating a conservative investment strategy[20] - The company has committed to not engaging in competitive businesses that could harm its interests or those of its shareholders[18] - The company has adhered to its commitments regarding the non-transfer of shares by certain shareholders, ensuring stability in its shareholding structure[18] - The company has conducted investor communications regarding its erythritol project and overall business operations, indicating transparency with stakeholders[24] - The first quarter report for 2021 was not audited, indicating that the figures presented are preliminary and subject to change[54]